Kamilla J. A. Bigos

Kamilla J. A. Bigos

Auto-generated profile, based on publicly available information

Kamilla J. A. Bigos

The University of Manchester, Division of Cancer Sciences, School of Medicine, Faculty of Biology Medicine and Health, Manchester, U.K.

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2020 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
PAParis Avgoustou
Paris Avgoustou
Ameera JailaniAmeera Jailani
Ameera Jailani
JZJean-Olivier Zirimwabagabo
Jean-Olivier Zirimwabagabo
MTMatthew J. Tozer
Matthew J. Tozer
KGKarl R. Gibson
Karl R. Gibson
GRGareth Owain Richards
Gareth Owain Richards

22 June 2022 in Expert Opinion on Drug Discovery
Verified
Journal Article
Open access
Ameera JailaniAmeera Jailani
Ameera Jailani
KBKamilla J. A. Bigos
Kamilla J. A. Bigos
PAParis Avgoustou
Paris Avgoustou
JEJoseph L. Egan
Joseph L. Egan
RHRobert A. Hathway
Robert A. Hathway
GRGareth Owain Richards
Gareth Owain Richards
Adrenomedullin (AM) is a peptide responsible for many physiological processes including vascular health and hormone regulation. Dysregulation of AM signaling can stimulate cancers by promoting prol...

25 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
ADAnubhav Datta
Anubhav Datta
LBLuisa Vanesa Biolatti
Luisa Vanesa Biolatti
MRMark Reardon
Mark Reardon
KBKamilla Bigos
Kamilla Bigos
SLSapna Lunj
Sapna Lunj
ACAnanya Choudhury
Ananya Choudhury
Background: Tumour hypoxia is a major determinant of treatment resistance and poor prognosis in cervical cancer but remains difficult to assess in clinical practice. Gene expression signatures offer a potential means to characterise hypoxia-related biology. This study aimed to develop and validate a hypoxia-associated gene expression signature for cervical cancer. Methods: RNA sequencing was performed on five cervical cancer cell lines exposed to normoxia (21% O₂) and hypoxia (1% O₂). Differentially expressed genes were mapped to The Cancer Genome Atlas cervical cancer cohort (TCGA-CESC) to train a 55-gene hypoxia classifier using k-means clustering and Prediction Analysis for Microarrays. The model was validated in an institutional Manchester cohort (n=153) and two public datasets from Seoul (n=300) and Oslo (n=283). Results: The Manchester 55-gene signature was enriched for canonical hypoxia pathways. In the Manchester cohort, hypoxia classification correlated with advanced FIGO stage, nodal involvement, tumour size ≥ 4 cm, and hydronephrosis ( adjusted p <0.05). Hypoxic tumours showed reduced overall survival (OS) and progression-free survival (PFS) in all cohorts. In multivariable models, the signature remained independently prognostic for OS in both TCGA (HR 1.70, 95% CI 1.10–2.60, p =0.012) and Manchester (HR 1.95, 95% CI 1.08–3.51, p =0.026). A direct comparison with a published 6-gene hypoxia signature in the Oslo cohort demonstrated 71% concordance in classification. Conclusions: Our 55-gene signature should be tested prospectively in trials to assess its ability to stratify patients for hypoxia-targeted therapies.